2022
Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis
Sutton T, Wong L, Walker B, Dewey E, Eil R, Lopez C, Kardosh A, Chen E, Rocha F, Billingsley K, Mayo S. Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis. Surgery 2022, 173: 1314-1321. PMID: 36435651, DOI: 10.1016/j.surg.2022.10.019.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesColorectal NeoplasmsHepatectomyHumansLiver NeoplasmsNeoplasm Recurrence, LocalRetrospective StudiesConceptsColorectal liver metastasesPost-recurrence overall survivalRepeat hepatic resectionRecurrent colorectal liver metastasesHepatic resectionLiver metastasesSystemic treatmentOverall survivalIntrahepatic recurrenceOncologic outcomesSystemic therapyMedian post-recurrence overall survivalRetrospective single-institution cohort studySingle-institution cohort studyCurative-intent hepatectomyImproved oncologic outcomesPerioperative systemic therapyRelevant clinicopathologic variablesSignificant clinicopathologic differencesPropensity-matched analysisRole of resectionCox proportional hazardsLiver recurrencePerioperative chemotherapyCohort study
2020
Effect of Time to Surgery of Colorectal Liver Metastases on Survival
Chen EY, Mayo SC, Sutton T, Kearney MR, Kardosh A, Vaccaro GM, Billingsley KG, Lopez CD. Effect of Time to Surgery of Colorectal Liver Metastases on Survival. Journal Of Gastrointestinal Cancer 2020, 52: 169-176. PMID: 32086781, PMCID: PMC7900034, DOI: 10.1007/s12029-020-00372-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTime FactorsTime-to-TreatmentYoung AdultConceptsColorectal liver metastasesLong-term OSPostoperative overall survivalOverall survivalLonger TTSLiver metastasesWorse survivalDiagnosis of CLMLong-term survivorsResultsTwo hundred eightyRisk of recurrenceComprehensive cancer centerHigh disease burdenSpecific primary tumorsShorter TTSPerioperative chemotherapyPostoperative chemotherapyPerioperative treatmentResection marginsCancer CenterMetastasis characteristicsInstitutional databasePrimary tumorDisease burdenSimilar survival
2013
Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy
Gur I, Diggs B, Wagner J, Vaccaro G, Lopez C, Sheppard B, Orloff S, Billingsley K. Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy. Journal Of Gastrointestinal Surgery 2013, 17: 2133-2142. PMID: 24091909, DOI: 10.1007/s11605-013-2295-1.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesPreoperative chemotherapyPerioperative chemotherapyOverall survivalLiver metastasesAdvanced ageResectable colorectal liver metastasesPreoperative portal vein embolizationShorter disease-free intervalAcademic oncology centerOutcomes Following ResectionThirty-day mortalityDisease-free intervalHigh-risk patientsPortal vein embolizationSubset of patientsPoor overall survivalLiver recurrenceSynchronous diseaseEleven patientsPostoperative complicationsRepeat resectionLiver resectionVein embolizationRetrospective review
2012
Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer
Hessman C, Bubbers E, Billingsley K, Herzig D, Wong M. Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer. The American Journal Of Surgery 2012, 203: 649-653. PMID: 22405917, PMCID: PMC4285581, DOI: 10.1016/j.amjsurg.2012.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAldehyde Dehydrogenase 1 FamilyColorectal NeoplasmsHumansIsoenzymesNeoplasm StagingNeoplastic Stem CellsRetinal DehydrogenaseConceptsAldehyde dehydrogenase 1Cancer stem cellsClinical outcomesLoss of expressionCSC marker aldehyde dehydrogenase 1Advanced stage colorectal cancerMarker expressionMetastatic CRC samplesAmerican Joint CommitteeLate-stage diseaseColorectal cancer progressionEffective therapeutic targetNonmetastatic CRCMetastatic diseaseEarly CRCALDH1 expressionColorectal cancerCancer stageCRC tumorsCRC samplesTumors variesDisease prognosisNonmetastatic tumorsTherapeutic targetJoint Committee
2011
Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases
Hammill C, Billingsley K, Cassera M, Wolf R, Ujiki M, Hansen P. Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases. Annals Of Surgical Oncology 2011, 18: 1947-1954. PMID: 21399885, DOI: 10.1245/s10434-010-1535-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedCatheter AblationCohort StudiesColorectal NeoplasmsCombined Modality TherapyFemaleFollow-Up StudiesHumansLaparoscopyLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPreoperative CareProspective StudiesRetrospective StudiesSurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsColorectal liver metastasesLaparoscopic radiofrequency ablationResectable colorectal liver metastasesRadiofrequency ablationResectable groupHepatic resectionLiver metastasesUnresectable groupMedian disease-free survivalComparable long-term survivalOutcomes of patientsDisease-free survivalKaplan-Meier methodLog-rank testLong-term survivalDiagnostic imaging studiesFavorable morbidityCRLM patientsPostoperative mortalityUnresectable diseaseMajor complicationsTumor numberResultsA totalSurgical oncologistsOutcome data
2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimens
2000
Follow-up care for cancer: making the benefits equal the cost.
Schwartz D, Billingsley K, Wallner K. Follow-up care for cancer: making the benefits equal the cost. Oncology 2000, 14: 1493-8, 1501; discussion 1502-5. PMID: 11098513.Peer-Reviewed Original ResearchMeSH KeywordsAftercareBreast NeoplasmsColorectal NeoplasmsFemaleFollow-Up StudiesHumansMaleNeoplasmsProstatic NeoplasmsQuality of LifeConceptsRecent consensus recommendationsSurvey of cliniciansInstitutional followUnproven regimensClinical outcomesClose surveillanceCommon cancerOncologic practiceConsensus recommendationsOncology organizationsFollowCancerCliniciansCareCurrent dataSignificant benefitsRegimensColorectalPatientsProstateBreastAcute need